ESTRO 37 Abstract book

S920

ESTRO 37

Results 18 patients received SABR with a median age was 69 years (range 58-88). 14 were men and 4 women. The median follow-up was 11 months (9.8-18.4months). The main sites of the primary tumor were: lung with 11 patients, colon and rectum with 5, thymus and soft tissue with 1. The most common histology was: adenocarcinoma in 8 patients, epidermoid 4, leimyosarcoma 1, thymoma 1 and unconfirmed 3. The fractionation more used was 50 Gy / 10Gy / fraction in 6 patients, 60Gy / 12Gy / fraction in 4 patients, 52.5Gy / 7.5Gy / fraction in 2 patients, 54Gy / 18Gy / fraction in 2 patients, 37.5Gy / 5.5Gy / fraction in 2 patients, 44Gy / 12Gy / fraction in 1 patient and 45Gy / 15Gy / fraction in 1 patient. In 88% of the patients, 16 in total, the SABR were performed in lung and in 11% (2 patients) were administrated to the lung and the liver. In 61.1% of the patients (11) the intention of the treatment was radical, 33.3% (6 patients) special palliative and 5.5% (1 patient) rescue. The tumor stage was: 61.1% stage IV, IA 22.2%, IB 11.1%, 5.5% IIIB. The most frequent size was 10-20mm in 8 patients, 30- 40mm in 4, 20-30mm in 3,> 50mm in 3, 0-10mm in 2. The most frequent localization of metastases in lung was: IRL in 6 patients, SRL 5, SLL 3, ILL 3 and in liver segment II 2 patients. At 3 months, 8 patients had stable disease (EE), 4 response partial (PR), 3 complete response (CR), 1 disease progression. At 6 months 6 patients had progressed, 3 in CR, 2 EE and 1 RP. The 77.7% of the patients (14) had no acute toxicity, 22.2% (4) presented different degrees of toxicity (dysphagia G2 1 patient, asthenia G1 1 patient, mild pain 2 patients). 83.3% (15) of the patients did not present late toxicity and only 16% (3) presented G2 pneumonitis. Conclusion The treatment with SABR in patients with metastatic disease seems feasible and similar in terms of local control, without presenting acute and late acute toxicity.